Michael Rodamer

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy

Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients

Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency

Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy

Water stable metal-organic framework packed microcolumn for online sorptive extraction and direct analysis of naproxen and its metabolite from urine sample

Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the “Cocktail” Approach

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid

Applications of AmpliChip??? CYP450

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation

Water Stability and Adsorption in Metal–Organic Frameworks

Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study

Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation

Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB

New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability

An LC–MS/MS procedure for the quantification of naproxen in human plasma: Development, validation, comparison with other methods, and application to a pharmacokinetic study

Cytochrome P 450 2C9 phenotyping using low-dose tolbutamide

Should We Use N -Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?